New Translational Data Highlights Bavituximab’s Ability to Induce Signs of Immune Activation in Lung Cancer Tumor Samples With Negative PD-L1 Expression
September 08, 2015 08:05 ET | Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 08, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
Peregrine Pharmaceuticals Presents Data at Annual Immunotherapy and Vaccine Summit (ImVacS) Supporting Ability of Bavituximab to Mediate Anti-Tumor T Cell Responses Across Multiple Tumor Types
August 26, 2015 09:00 ET | Peregrine Pharmaceuticals Inc.
- Increasing Activated T Cells in Tumors Demonstrates Potential Complement to anti-PD-1 and anti-PD-L1 Checkpoint Inhibitors - - Clinical and Preclinical Studies Demonstrate Estimated Survival...